Defects in homologous recombination can lead to genomic instability and increase the risk of oncogenesis. Mutations in genes involved in HR, such as BRCA1 and BRCA2, are strongly associated with hereditary breast and ovarian cancers. These mutations impair the HR process, leading to an accumulation of DNA damage and subsequent cancer development.
